zipjet: I have a business question for you about Teva.
One reason Teva is so aggressive with at-risk generic-drug launches is that Teva has insurance for the possibility of an adverse legal ruling (and potentially the awarding of treble damages).
As a % of the at-risk sales, how much do you think Teva has to pay for this kind of insurance? T.i.a.
Wish the best for your wife. Just curious if you/she would consider Campath if it gets approved for MS. I don't follow the MS space as closely as others but it appears to have potentially better efficacy but with a monitoring concern.
Market Data 
Markets 
AI
